Sitagliptin (DPP4 inhibitor)

DRUG4 trials

Sponsors

Vanderbilt University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Second Affiliated Hospital of Guangzhou Medical University, Tanta University

Conditions

Breast CancerColorectal CancerDiabetes Type 2HypertensionType 2 Diabetes

Phase 1

Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC

Not yet recruitingNCT07365592

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityColorectal Cancer

Start: 2026-01-01End: 2029-12-31Target: 138Updated: 2026-01-26

Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

RecruitingNCT07374328

Second Affiliated Hospital of Guangzhou Medical UniversityType 2 Diabetes

Start: 2025-06-01End: 2026-08-31Target: 240Updated: 2026-01-28

Phase 4

Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC

Not yet recruitingNCT07436663

Tanta UniversityBreast Cancer

Start: 2026-02-01End: 2027-12-01Target: 150Updated: 2026-02-27

Unknown Phase

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

CompletedNCT01413542

Vanderbilt UniversityDiabetes Type 2, Hypertension

Start: 2011-11-30End: 2014-07-31Updated: 2015-11-04

Related Papers

Dipeptidyl‐Peptidase 4 Inhibition and the Vascular Effects of Glucagon‐like Peptide‐1 and Brain Natriuretic Peptide in the Human Forearm

Journal of the American Heart Association2014-08-1538 citations

Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition

Hypertension2014-02-1165 citations